Xeris Biopharma Posts Encouraging Data From Reformulated Thyroid Hormone Deficiency Treatment In Healthy Participants

• Xeris Biopharma Holdings Inc (NASDAQ: XERS) announced topline results from its Phase 1 study of subcutaneous (SC) levothyroxine (XP-8121) in healthy adult volunteers.

• Using its XeriSol technology, the company is developing a novel levothyroxine sodium (SC injection) formulation to potentially mitigate certain challenges associated with oral formulations.

• The Phase 1 study was conducted in 60 healthy adults.

• The study was designed to evaluate the pharmacokinetics, dose proportionality, and safety and tolerability of 600 μg, 1200 μg, and 1500 μg of XP-8121 following SC administration versus oral (PO) levothyroxine (Synthroid ).

• Synthroid is used to treat thyroid hormone deficiency.

• The data show that subjects receiving XP-8121 SC have slower absorption, lower peak plasma, and higher extended exposure compared to Synthroid PO at the comparable dose of 600 μg.

• In addition, exposure was proportional over the range of ascending XP-8121 doses studied.

• Single SC doses of XP-8121 at all doses were safe and well tolerated.

• Price Action: XERS shares are up 5.28% at $1.30 on the last check Thursday.

See more from Benzinga

• Talaris Therapeutics Reports Patient Death In Late-Stage Trial Of Experimental Drug For Graft vs Host Disease

• Freeport-McMoRan Q3 Profits, Sales Fall On Decreasing Copper Prices

• 'World War 3 Has Already Started': 'Dr. Doom' Nouriel Roubini On What Could Ignite The Cold War Into A Ho

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.